SCHEMBL5550269

SCHEMBL5550269

Cc1c(C(N)=O)sc2cncc(Nc3ccc(Br)cc3)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 2/20 0.42
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
DHODH Q02127 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PIM1 P11309 2/20 0.39
PRKACA P17612 2/20 0.39
CSNK1A1 P48729 2/20 0.39
CLK2 P49760 2/20 0.39
GSK3A P49840 2/20 0.39
GSK3B P49841 2/20 0.39
RPS6KA3 P51812 2/20 0.39
CDK5 Q00535 2/20 0.39
MAP4K2 Q12851 2/20 0.39
ROCK1 Q13464 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
DAPK3 O43293 1/20 0.39
PRKD3 O94806 1/20 0.39
FLT1 P17948 1/20 0.39
LTK P29376 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7055499 0.90 MAP3K8 (0.44) MAP3K8MAPTKDM4EPIM1PRKACA
SCHEMBL5550746 0.89 GPR35 (0.43) MAP3K8MAPTKDM4EDHODHNPSR1
SCHEMBL5550510 0.87 ALDH1A1 (0.46) MAP3K8MAPTKDM4EDHODHNPSR1
SCHEMBL7053701 0.76 ICAM1 (0.58) PIM1PRKACACSNK1A1CLK2GSK3A
SCHEMBL7057425 0.74 ICAM1 (0.48) NPSR1PIM1PRKACACSNK1A1CLK2
SCHEMBL5554072 0.73 MAP3K8 (0.74) MAP3K8PIM1PRKACACSNK1A1CLK2
SCHEMBL21500667 0.69 PIM1 (0.53) MAP3K8MAPTPIM1PRKACACSNK1A1
SCHEMBL5550182 0.67 MAP3K8 (0.76) MAP3K8PIM1PRKACACSNK1A1CLK2
SCHEMBL7857515 0.65 ALDH1A1 (0.41) MAPTPIM1PRKACACSNK1A1CLK2
SCHEMBL7052567 0.64 CDK8 (0.58) PIM1MAP4K2MAP2K2CDK8CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 MAP3K8 13/4885MAPT 2339/4885KDM4E 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.